@article {doi:10.1002/anie.201708529,
	title = {Biological Imaging with Medium-Sensitive Bichromatic Flexible Fluorescent Dyes},
	journal = {Angewandte Chemie International Edition},
	volume = {56},
	number = {49},
	year = {Submitted},
	pages = {15603-15606},
	abstract = {Abstract A family of environment-sensitive shape-shifting molecules have been developed as flexible fluorescent (FlexFluor) dyes for biological imaging applications. These compounds feature a flexible bithiophene-based fluorophore that gives rise to different emission colors in lipophilic or hydrophilic environments, as well as side groups that can be synthetically modified with ease. FlexFluor dyes are the first fluorescent dyes in which emission color can be used to indicate lipid/water environments. The behavior of these dyes in different solvents was studied, and used to simultaneously highlight lipid and water contents in adipose and brain tissues using optical fluorescence microscopy.},
	keywords = {ADIPOCYTES, bichromatic dyes, lipophilicity, myelin sheath, NEURONS},
	doi = {10.1002/anie.201708529},
	url = {https://onlinelibrary.wiley.com/doi/abs/10.1002/anie.201708529},
	author = {Cao Yang and Wang Xiaozhu and Shi Xiaolei and Clee Susanne M. and McGeer Patrick L. and Wolf Michael O. and Orvig Chris}
}
@article {ANIE:ANIE201708529,
	title = {Biological Imaging with Medium-Sensitive Bichromatic Flexible Fluorescent Dyes},
	journal = {Angew. Chem. Int. Ed.},
	volume = {56},
	number = {49},
	year = {2017},
	pages = {15603{\textendash}15606},
	keywords = {ADIPOCYTES, bichromatic dyes, lipophilicity, myelin sheath, NEURONS},
	issn = {1521-3773},
	doi = {10.1002/anie.201708529},
	url = {http://dx.doi.org/10.1002/anie.201708529},
	author = {Cao, Yang and Wang, Xiaozhu and Shi, Xiaolei and Clee, Susanne M. and McGeer, Patrick L. and Wolf, Michael O. and Orvig, Chris}
}
@article {4399,
	title = {Kinetic analysis and comparison of uptake, distribution, and excretion of V-48-labeled compounds in rats},
	journal = {Journal of Applied Physiology},
	volume = {84},
	number = {2},
	year = {1998},
	note = {ISI Document Delivery No.: YU964Times Cited: 63Cited Reference Count: 43},
	month = {Feb},
	pages = {569-575},
	type = {Article},
	abstract = {Vanadium has been found to be orally active in lowering plasma glucose levels; thus it provides a potential treatment for diabetes mellitus. Bis(maltolato)oxovanadium(rv) (BMOV) is a well-characterized organovanadium compound that has been shown in preliminary studies to have a potentially useful absorption profile. Tissue distributions of BMOV compared with those of vanadyl sulfate (VS) were studied in Wistar rats by using V-48 as a tracer. In this study, the compounds were administered in carrier-added forms by either oral gavage or intraperitoneal injection. Data analyzed by a compartmental model, by using simulation, analysis, and modeling (i.e., SAAM II) software, showed a pattern of increased tissue uptake with use of V-48-BMOV compared with (VS)-V-48. The highest V-48 concentrations at 24 h after gavage were in bone, followed by kidney and liver. Most ingested V-48 was eliminated unabsorbed by fecal excretion. On average, V-48 concentrations in bone, kidney, and liver 24 h after oral administration of V-48-BMOV were two to three times higher than those of (VS)-V-48, which is consistent with the increased glucose-lowering potency of BMOV in acute glucose lowering compared with VS.},
	keywords = {ADIPOCYTES, analysis, and modeling, BIS(MALTOLATO)OXOVANADIUM(IV), compartmental modeling, diabetes, DISSOCIATION, FERRIC MALTOL, GLUCOSE, INDUCED DIABETIC RATS, INSULIN, insulin mimetic, METABOLISM, MOLYBDENUM, SIMULATION, SMALL-INTESTINE, Software, VANADIUM, VANADYL SULFATE},
	isbn = {8750-7587},
	url = {<Go to ISI>://000071774300025},
	author = {Setyawati, I. A. and Thompson, K. H. and Yuen, V. G. and Sun, Y. and Battell, M. and Lyster, D. M. and Vo, C. and Ruth, T. J. and Zeisler, S. and McNeill, J. H. and Orvig, Chris}
}
@article {3690,
	title = {Characterization of the potent insulin mimetic agent bis(maltolato)oxovanadium(IV) (BMOV) in solution by EPR spectroscopy},
	journal = {Inorganic Chemistry},
	volume = {35},
	number = {22},
	year = {1996},
	note = {ISI Document Delivery No.: VP449Times Cited: 63Cited Reference Count: 48},
	month = {Oct},
	pages = {6507-6512},
	type = {Article},
	abstract = {{Bis(maltolato)oxovanadium(IV) (abbreviated BMOV or VO(ma)(2)) has been characterized by electron paramagnetic resonance (EPR) spectroscopy in CH2Cl2, H2O, MeOH, and pyridine at both room and low temperatures. Spin Hamiltonian parameters for mono- and bis(maltolato)oxovanadium(IV) complexes [VO(ma)](+) (=[VO(ma)(H2O)(n)](+)},
	keywords = {ADIPOCYTES, CHEMISTRY, DIABETIC RATS, ELECTRON-PARAMAGNETIC-RES, FUTURE, GLUCOSE, KINASE, MIMICS, SULFATE, treatment, VANADYL COMPLEXES},
	isbn = {0020-1669},
	url = {<Go to ISI>://A1996VP44900022},
	author = {Hanson, G. R. and Sun, Y. and Orvig, Chris}
}
@article {3447,
	title = {Increased potency of vanadium using organic ligands},
	journal = {Molecular and Cellular Biochemistry},
	volume = {153},
	number = {1-2},
	year = {1995},
	note = {ISI Document Delivery No.: TM620Times Cited: 45Cited Reference Count: 46Vanadium SymposiumJUL 29-31, 1994MONTREAL, CANADACanadian Diabet Assoc, Fonds Rech Sante Quebec, Juvenile Diabet Fdn Canada, Marion Merrell Dow Canada, McGill Univ, Med Res Council Canada, Medisense Canada Inc, Merck Frosst, Canada Inc, Miles Canada Inc},
	month = {Dec},
	pages = {175-180},
	type = {Proceedings Paper},
	abstract = {The in vivo glucose lowering effect of orally administered inorganic vanadium compounds in diabetes was first reported in our laboratory in 1985. While both vanadate and vanadyl forms of vanadium are orally active, they are still not well absorbed. We have synthesized several organic vanadium compounds and one compound, bis(maltolato)oxovanadium(lv) or BMOV, has been extensively investigated. BMOV proved effective in lowering plasma glucose and lipids in STZ-diabetic: rats when administered in drinking water over a 25 week period. The maintenance dose (0.18 mmol/kg/day) was approximately 50\% of that required for vanadyl sulfate (VS). Secondary complications of diabetes were prevented by BMOV and no marked toxicity was noted. Oral gavage of STZ-diabetic rats with BMOV also reduced blood glucose levels. The ED(50) for BMOV was 0.5 mmol/kg, while for VS the estimated ED(50) was 0.9 mmol/kg. BMOV was also effective by the intraperitoneal route in STZ-diabetic rats. The ED(50) was 0.08 mmol/kg compared to 0.22 mmol/kg for VS. Some animals treated p.o. or i.p. remained euglycemic for up to 14 weeks. An i.v. infusion of BMOV of 0.05 mmol/kg over a 30 min period reduced plasma glucose levels by 50\% while VS was not effective.},
	keywords = {ADIPOCYTES, BIS(MALTOLATO)OXOVANADIUM(IV), diabetes, DIABETIC, GLUCOSE, HYPERTENSION, IMPROVEMENT, INSULIN ACTION, insulin-mimetic, RATS, RECEPTOR TYROSINE KINASE, resistance, SPONTANEOUSLY HYPERTENSIVE RATS, VANADATE, VANADIUM},
	isbn = {0300-8177},
	url = {<Go to ISI>://A1995TM62000024},
	author = {McNeill, J. H. and Yuen, V. G. and Dai, S. T. and Orvig, Chris}
}
@article {2940,
	title = {GLUCOSE-LOWERING EFFECTS OF A NEW ORGANIC VANADIUM COMPLEX, BIS(MALTOLATO)OXOVANADIUM(IV)},
	journal = {Canadian Journal of Physiology and Pharmacology},
	volume = {71},
	number = {3-4},
	year = {1993},
	note = {ISI Document Delivery No.: LN775Times Cited: 84Cited Reference Count: 39},
	month = {Mar-Apr},
	pages = {263-269},
	type = {Article},
	abstract = {Inorganic vanadium has been shown, both in vivo and in vitro, to have insulin-mimetic properties. A new organic vanadium complex, bis(maltolato)oxovanadium(IV) (BMOV), was developed to increase the absorption of vanadium from the gastrointestinal tract, thereby reducing the dose of vanadium necessary to produce glucose-lowering effects. BMOV was administered in the drinking water for 25 weeks to control and streptozotocin-induced diabetic, male Wistar rats. BMOV treatment produced a stable euglycemic state in 70\% of diabetic treated animals. The other 30\% of the diabetic treated animals demonstrated fluctuations in glucose control over the entire study period. The initial effective dose of BMOV was 0.45 mmol/kg, which decreased to an effective maintenance dose of 0. 18 mmol/kg, significantly lower than the dose of inorganic vanadium salts used in previous studies. BMOV treatment did significantly reduce fluid consumption levels in control treated animals after 10 weeks of therapy; however, the food consumption for control treated animals was only intermittently lower than that for controls. Plasma cholesterol and triglyceride levels were normalized with BMOV treatment for all diabetic treated animals, without a concomitant increase in plasma insulin levels. An oral glucose tolerance test demonstrated that glucose homeostasis in control-treated animals occurred at significantly lower plasma insulin levels than in control animals. BMOV effectively produced the glucose-lowering effects at significantly lower dose than previously used for inorganic vanadium salts, without any overt signs of toxicity.},
	keywords = {ACTIVATION, ADIPOCYTES, BIS(MALTOLATO)OXOVANADIUM(IV), BLOOD-GLUCOSE, DIABETES TREATMENT, DIABETIC RATS, GLYCOLYSIS, INSULIN, SENSITIVITY, SKELETAL-MUSCLE, STIMULATION, streptozotocin-induced diabetes, VANADATE},
	isbn = {0008-4212},
	url = {<Go to ISI>://A1993LN77500013},
	author = {Yuen, V. G. and Orvig, Chris and McNeill, J. H.}
}
@article {7324,
	title = {BIS(MALTOLATO)OXOVANADIUM(IV) IS A POTENT INSULIN MIMIC},
	journal = {Journal of Medicinal Chemistry},
	volume = {35},
	number = {8},
	year = {1992},
	note = {ISI Document Delivery No.: HQ011Times Cited: 272Cited Reference Count: 22},
	month = {Apr},
	pages = {1489-1491},
	type = {Letter},
	keywords = {ADIPOCYTES, COMPLEXES, DIABETIC RATS, PEROXIDE(S), RECEPTOR KINASE, VANADYL TREATMENT},
	isbn = {0022-2623},
	url = {<Go to ISI>://A1992HQ01100020},
	author = {McNeill, J. H. and Yuen, V. G. and Hoveyda, H. R. and Orvig, Chris}
}
